Please log in to determine if you are eligible to purchase PT Programs.
POST-IMMUNOTHERAPY FLOW ANALYSIS - FL6
FL6
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Procedure
Challenges per Shipment
Number of Shipments
Post-immunotherapy flow cytometry analysis
3
Two online activities per year; your CAP shipping contact will be notified via email when the activity is available
Program FL6 is appropriate for laboratories that perform flow cytometry analysis on specimens from patients treated with immunotherapy regimens that cause immunophenotypic changes to normal and/or neoplastic cells. These include anti-CD20 (rituximab), anti-CD19 (CAR T19), and anti-CD38 therapies (daratumumab), among others.
Participation in this program alone does not satisfy proficiency testing requirements for laboratories performing more general analysis of leukemia/lymphoma specimens.
Program Information
Three online cases consisting of gated dot plots, clinical histories, and pertinent laboratory data, as well as images of tissue sections, bone marrow, and/or peripheral blood smears as clinically relevant and/or available
Online, whole slide images powered by DigitalScope® technology (if applicable)
Help
